^
Association details:
| Biomarker: | ALK rearrangement + PD-L1 overepxression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Investigation on the Survival Implications of PD-L1 Expression Status in ALK- Rearranged Advanced Non-Small Cell Lung Cancer Treated with First-line Crizotinib
Published date:
04/05/2022
Excerpt:
...we retrospectively analyzed the baseline PD-L1 expression levels using immunohistochemistry 22C3 assay of tissue samples from 128 patients with ALK-rearranged advanced lung adenocarcinoma who were treated with first-line crizotinib….A subset of patients with ALK-rearranged NSCLC having high baseline PD-L1 expression level (TPS of ≥50%) had poorer survival outcomes despite crizotinib therapy.
DOI:
https://doi.org/10.1016/j.lungcan.2022.04.002
